With the rise in popularity of weight loss drugs such as Ozempic, discussions about weight loss are once again ramping up. But while some people are open about using medication to slim down — or slimming down as a result of using medication to treat a condition such as type 2 diabetes — others consider commenting on or speculating about someone

(CNN) - About one in eight adults said they have taken a GLP-1 drug like Ozempic or Mounjaro, according to a new poll from KFF. About 6% of respondents say they are currently taking the popular drugs.

Novo Nordisk signed a research tie-up with U.S. biotech firm Metaphore on Thursday to develop next-generation obesity drugs.

The company behind blockbuster drugs Ozempic and Wegovy wants to keep the gravy train running. Expanding an earlier deal, it announced Thursday that it will pay U.S. company Metaphore Biotechnologies as much as $600 million to help it develop new medicines.

Flagship Pioneering’s Metaphore unit announced a new collaboration with partner Novo Nordisk (NVO) for the research and development of next-generation obesity management treatments. The collaboration will utilize Metaphore’s MIMIC platform for the discovery and development of up to two therapeutics targeted at the GLP-1 receptor and related

An obesity-focused startup that spun out of Cambridge’s Flagship Pioneering last year has forged a partnership with the Danish pharmaceutical giant behind weight-loss drugs Ozempic and Wegovy.